Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LGLQ for Mild COVID-19
NCT06355193Phase 1Completed
- Sponsor
- Central South University
- Start
- Nov 2022
- Primary completion
- Dec 2022
- Modality
- PE (Plant Extract)
- Countries
- 1
01
Overview
Phase 1, randomised trial of Langenlianqiao in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Central South University. Primary endpoint: Treatment and symptomatic improvement effects at 1 month. Started Nov 2022; status: completed.
02
Drugs
Langenlianqiao
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06355193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06355193.